Related Experiment Video
Updated: Aug 4, 2026
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
PROMACE-MOPP and intrathecal chemotherapy for CNS lymphomas
Journal of Neuro-Oncology
|April 1, 1996
Summary
This Phase II study shows that the PROMACE-MOPP regimen with intrathecal therapy and cranial radiation is effective for central nervous system (CNS) lymphomas. However, the treatment regimen is associated with substantial toxicity, including a fatal case of pneumocystis pneumonia.
Area of Science:
- Oncology
- Neurology
- Pharmacology
Background:
- Diffuse large cell lymphomas (DLBCL) can involve the central nervous system (CNS), requiring specific treatment strategies.
- Limited data exists on the efficacy and toxicity of combined chemotherapy, intrathecal therapy, and radiation for CNS lymphomas.
Purpose of the Study:
- To evaluate the efficacy and toxicity of the PROMACE-MOPP regimen combined with intrathecal (IT) therapy and cranial radiation in patients with CNS lymphomas.
Main Methods:
- A Phase II study was conducted on 7 patients with CNS diffuse large cell lymphomas.
- Treatment included PROMACE-MOPP chemotherapy, intrathecal methotrexate and hydrocortisone, and whole brain radiation therapy.
- Patient response and toxicity were assessed throughout the study.
Main Results:
- After PROMACE chemotherapy, 3 patients achieved a complete response (CR), 2 had a partial response (PR), and 1 was stable.
- Following PROMACE +/- MOPP, 6 out of 7 patients achieved CR.
- Median survival was 100 weeks, but significant toxicities were observed, including febrile neutropenia and one fatal case of pneumocystis pneumonia.
Conclusions:
- The PROMACE-MOPP regimen, combined with IT therapy and cranial radiation, demonstrates activity in treating CNS lymphomas.
- The regimen is associated with substantial toxicity, necessitating careful patient monitoring and management.
